Vertex Pharmaceuticals Inc. (VRTX) News

Vertex Pharmaceuticals Inc. (VRTX): $281.79

1.44 (+0.51%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add VRTX to Watchlist
Sign Up

Industry: Biotech


Ranked

of 398

in industry

Filter VRTX News Items

VRTX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

VRTX News Highlights

  • VRTX's 30 day story count now stands at 45.
  • Over the past 28 days, the trend for VRTX's stories per day has been choppy and unclear. It has oscillated between 1 and 7.
  • The most mentioned tickers in articles about VRTX are AAPL, BEAT and MILE.

Latest VRTX News From Around the Web

Below are the latest news stories about Vertex Pharmaceuticals Inc that investors may wish to consider to help them evaluate VRTX as an investment opportunity.

Vertex Pharmaceuticals: Shares Up as Business Expands

Vertex Pharmaceuticals (VRTX) shares are up more than 27% over the past three months, after earnings rebounded from a 2021 second-quarter slump, created by higher research and development costs for certain collaborations.The company's fundamentals appear to be solid, as sales and earnings are growing on continued strong progress in the company's business. So, I'm bullish on this stock.Vertex Pharmaceuticals is a biotechnology developer of treatments for patients affected with cystic fibrosis (CF), an inherited disease that causes severe damage to the respiratory, digestive tract and other organs.The company markets Kaftrio in Europe and other non-U.S. countries, and Trikafta in the U.S.

Alberto Abaterusso on TipRanks | February 27, 2022

VIR Q4 Earnings Beat on Higher Revenues From Covid Treatment

VIR beat earnings estimates in the fourth quarter on higher sotrovimab revenues for COVID-19 patients.

Yahoo | February 25, 2022

Why Is Vertex (VRTX) Up 0.9% Since Last Earnings Report?

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Yahoo | February 25, 2022

Radius (RDUS) Q4 Earnings & Revenues Surpass Estimates

Radius (RDUS) beats on earnings and sales in the fourth quarter. The guidance is disappointing.

Yahoo | February 25, 2022

Aerie (AERI) Q4 Earnings Beat Estimates, Revenues Up Y/Y

Aerie (AERI) beats earnings and sales estimates for the fourth quarter of 2021. AERI's shares increase in the after-market trading session following the news.

Yahoo | February 25, 2022

Intellia (NTLA) Q4 Loss Wider Than Expected, Revenues Up Y/Y

Intellia Therapeutics (NTLA) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.

Yahoo | February 25, 2022

Three Shrewd Moves In A Bad Market By Top Fidelity Brains

In a bad market, what's one of the top Fidelity funds up to? Growth Discovery, one of the best mutual funds anywhere, is making three savvy moves.

Yahoo | February 25, 2022

Agios (AGIO) Loss Wider Than Expected in Q4, Revenues Nil

Agios Pharmaceuticals (AGIO) posts wider-than-expected loss for the fourth quarter of 2021. It does not record any revenues in the quarter.

Yahoo | February 24, 2022

Theravance's (TBPH) Q4 Earnings and Sales Miss Estimates

Theravance (TBPH) reports wider-than-expected loss for the fourth quarter of 2021. Revenues decline year over year.

Yahoo | February 24, 2022

Arena (ARNA) Q4 Loss Wider Than Expected, Etrasimod in Focus

Arena Pharmaceuticals (ARNA) misses on Q4 bottom line. Top-line data from several phase III studies on etrasimod are slated for release in 2022.

Yahoo | February 24, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.4602 seconds.